$225.66+1.92 (+0.86%)
IDEX Corporation, together with its subsidiaries, provides applied solutions in the United States, North America, Europe, Asia, and internationally.
IDEX Corporation in the Industrials sector is trading at $225.66 with a market capitalization of $17.6B. Wall Street consensus targets $255.57 (14 analysts), implying a +13.3% move over the next 12 months. The stock is currently 7% below its 52-week high of $243.80, remaining 10.0% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $920.60M↑ | $886.90M↓ | $899.10M↑ | $878.70M↑ | $865.40M |
| Gross Profit | $426.80M↑ | $398.10M↑ | $387.10M↓ | $390.60M↓ | $392.20M |
| Operating Income | $202.70M↑ | $179.80M↓ | $186.00M | $185.90M↓ | $188.60M |
| Net Income | $143.40M↑ | $120.00M↓ | $128.30M↑ | $127.80M↓ | $131.60M |
IDEX Corporation, together with its subsidiaries, provides applied solutions in the United States, North America, Europe, Asia, and internationally. It operates through three segments: Health & Science Technologies (HST), Fluid & Metering Technologie...

IEX is gaining from strong data center, semiconductor, space and defense demand, acquisitions and shareholder returns.

IDEX trades at $230.28 and has moved in lockstep with the market. Its shares have returned 8.9% over the last six months while the S&P 500 has gained 12.3%.

Idex (IEX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IDEX has outperformed the broader market over the past year, and analysts are cautiously optimistic about the stock’s prospects.

Looking back on gas and liquid handling stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including IDEX (NYSE:IEX) and its peers.
Academic risk and quality models computed from IEX's own filings and price history, not from analyst opinion.
Strong on 8 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, level with the current 26.9% reading.
Fama-French 5-factor market beta. The five factors explain 34% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.